
Summit appoints two non-executive directors
pharmafile | November 26, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Frank Armstrong, Jim Mellon, summit
UK drug discovery and development firm Summit has appointed Jim Mellon and Dr Frank Armstrong as non-executive directors.
The additions are part of the company’s previously announced strategic shift to focus on its clinical-stage programmes for the treatment Duchenne Muscular Dystrophy (DMD) and C. difficile infections.
Mellon (pictured) is a renowned investor and entrepreneur with interests in several industries. He is an active investor in the biopharma industry and is a non-executive director of the UK biotech firm Plethora Solutions, and of the biopharma investment company, Port Erin BioPharma.
Armstrong is an experienced, medically qualified pharma executive who has worked at Board level at a number of companies in the UK, US, Switzerland and Germany. He has extensive experience of all aspects of medical and product development in large and small companies, and has led successful product approvals in the US and Europe across a range of therapeutic areas.
“Jim and Frank will bring considerable business, clinical and product development expertise to support the future growth of Summit,” commented Dr Barry Price, chairman of Summit.
With the appointment of the new directors, Dr Richard Storer, Dr Andy Richards and George Elliott will be stepping down from the Board effective immediately. Price added: “On behalf of the Board, I would sincerely like to thank Dick, Andy and George for their contribution towards the development of Summit over many years.”






